Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

every administration, there’s been a health care factor,” David Elkins, the chief financial official of Bristol Myers Squibb, ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ownership structure of the business. The group holding the most number of ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.